# US 2023/0406815 A1 · Crystalline prostacyclin (ip) receptor agonist and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406815 A1
- Document ID: US20230406815A1
- Status: Published application
- Kind: A1
- Application number: 18/169,016
- Filed: 2023-02-14
- Published: 2023-12-21
- Earliest claimed: 2022-02-15
- Assignees: United Therapeutics Corporation
- Applicants: United Therapeutics Corporation
- Inventors: Kenneth PHARES
- Web page: https://patentgrep.com/patent/US20230406815A1

## CPC

- A61P 9/12: Antihypertensives
- C07C 271/28: to a carbon atom of a non-condensed six-membered aromatic ring
- C07C 269/08: Separation; Purification; Stabilisation; Use of additives
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.

## Claims

### Claim at position 1

1-43. (canceled)

### Claim 44

An amorphous form of ralinepag that is characterized as having an X-Ray powder diffraction (XRPD) pattern showing a lack of crystallinity, as shown in FIG. 5.

### Claim 45 (depends on 44)

The amorphous ralinepag of claim 44, wherein the amorphous ralinepag is further characterized as converting to a crystalline form of ralinepag on drying.

### Claim 46 (depends on 45)

The crystalline form of ralinepag of claim 45, wherein the crystalline form of ralinepag is characterized as having:
an XRPD pattern substantially the same as shown in FIG. 1 as measured using Cu Kα.radiation; or
an XRPD pattern with peaks at 8.8±0.2°2-Theta, 11.7±0.2°2-Theta, and 16.2±0.2°2-Theta as measured using Cu Kα.radiation; or
a Thermogravimetric/Differential Thermal Analysis (TGA/DTA) thermogram substantially the same as shown in FIG. 6; or
a Differential Scanning Calorimetry (DSC) thermogram substantially the same as shown in FIG. 7; or
unit cell parameters substantially equal to the following at 100 K:
Crystal System
triclinic
Space Group
P-1
a (Å)
10.1269(9)
b (Å)
10.7838(8)
c (Å)
11.1906(8)
α (°)
80.888(3)
β (°)
71.953(3)
γ (°)
68.331(4)
Volume (Å3)
1078.51(15)
Z, Z′
2, 1
Calculated Density (g/cm3)
1.330
Absorption coefficient (mm−1)
1.858
F(000)
456.0

### Claim 47 (depends on 44)

A solid form pharmaceutical composition comprising the amorphous ralinepag of claim 44 and at least one pharmaceutically acceptable excipient.

### Claim 48 (depends on 47)

The pharmaceutical composition of claim 47, wherein the pharmaceutical composition is suitable for administration to a subject by oral administration, intranasal administration, or inhalation.

### Claim 49 (depends on 47)

The pharmaceutical composition of claim 47, wherein the pharmaceutical composition is in the form of a tablet, a pill, or a capsule; or the pharmaceutical composition is administered to a subject with a dry powdered inhaler (DPI) or a metered dose inhaler (MDI).

### Claim 50 (depends on 44)

A method of treating pulmonary arterial hypertension (PAH) in a subject in need thereof, comprising administering the amorphous form of ralinepag of claim 44, wherein the subject has World Health Organization (WHO)/New York Heart Association (NYHA) functional class II to IV symptoms.

### Claim 51

A crystalline form of ralinepag that is characterized as having:
a) an XRPD pattern substantially the same as shown in FIG. 1 as measured using Cu Kα.radiation; or
an XRPD pattern with peaks at 8.8±0.2°2-Theta, 11.7±0.2°2-Theta, and 16.2±0.2°2-Theta as measured using Cu Kα.radiation; or
a Thermogravimetric/Differential Thermal Analysis (TGA/DTA) thermogram substantially the same as shown in FIG. 6; or
a Differential Scanning Calorimetry (DSC) thermogram substantially the same as shown in FIG. 7; or
unit cell parameters substantially equal to the following at 100 K:
Crystal System
triclinic
Space Group
P-1
a (Å)
10.1269(9)
b (Å)
10.7838(8)
c (Å)
11.1906(8
α (°)
80.888(3
β (°)
71.953(3)
γ (°)
68.331(4)
Volume (Å3)
1078.51(15)
Z, Z′
2, 1
Calculated Density (g/cm3)
1.330
Absorption coefficient (mm−1)
1.858
F(000)
456.0
or
a reversible water uptake of at most 0.2% (w/w) between 0% and 90% Relative Humidity (RH) as determined by Dynamic Vapour Sorption (DVS); or
an unchanged XRPD pattern after DVS analysis between 0% and 90% RH; or
b) an XRPD pattern substantially the same as shown in FIG. 2 as measured using Cu Kα.radiation; or
an XRPD pattern with peaks at 4.1±0.2°2-Theta, 15.5±0.2°2-Theta, and 16.9±0.2°2-Theta as measured using Cu Kα.radiation; or
a Thermogravimetric/Differential Thermal Analysis (TGA/DTA) thermogram substantially the same as shown in FIG. 8; or
a TGA/DTA thermogram showing weak endothermic and exothermic events from 81 to 89° C. and a broad endothermic event having an onset at about 124.7° C.; or
c) an XRPD pattern substantially the same as shown in FIG. 3 as measured using Cu Kα.radiation; or
an XRPD pattern with peaks at 3.6±0.2°2-Theta, 18.7±0.2°2-Theta, and 22.2±0.2°2-Theta as measured using Cu Kα.radiation; or
a Thermogravimetric/Differential Thermal Analysis (TGA/DTA) thermogram substantially the same as shown in FIG. 9; or
d) an XRPD pattern substantially the same as shown in FIG. 4 as measured using Cu Kα.radiation; or
an XRPD pattern with peaks at 15.0±0.2°2-Theta, 16.7±0.2°2-Theta, and 18.0±0.2°2-Theta as measured using Cu Kα.radiation; or
a Thermogravimetric/Differential Thermal Analysis (TGA/DTA) thermogram substantially the same as shown in FIG. 10.

### Claim 52 (depends on 51)

The crystalline form of ralinepag of claim 51, wherein the crystalline form of ralinepag is characterized as having:
an XRPD pattern with peaks at 8.8±0.2°2-Theta, 11.7±0.2°2-Theta, and 16.2±0.2°2-Theta as measured using Cu Kα radiation; and
a Differential Scanning Calorimetry (DSC) thermogram with a sharp endothermic event having an onset at about 127.5° C.; or a reversible water uptake of at most 0.2% (w/w) between 0% and 90% Relative Humidity (RH) as determined by Dynamic Vapour Sorption (DVS); or an unchanged XRPD pattern after DVS analysis between 0% and 90% RH.

### Claim 53 (depends on 51)

The crystalline form of ralinepag of claim 51, wherein the crystalline form of ralinepag is characterized as having:
an XRPD pattern substantially the same as shown in FIG. 1 as measured using Cu Kα.radiation; and
a Thermogravimetric/Differential Thermal Analysis (TGA/DTA) thermogram substantially the same as shown in FIG. 6; or a Differential Scanning Calorimetry (DSC) thermogram substantially the same as shown in FIG. 7.

### Claim 54 (depends on 51)

The crystalline form of ralinepag of claim 51, wherein the crystalline form of ralinepag is characterized as having:
an XRPD pattern with peaks at 4.1±0.2°2-Theta, 15.5±0.2°2-Theta, and 16.9±0.2°2-Theta as measured using Cu Kα.radiation; and
a TGA/DTA thermogram showing weak endothermic and exothermic events from 81 to 89° C. and a broad endothermic event having an onset at about 124.7° C.

### Claim 55 (depends on 51)

The crystalline form of ralinepag of claim 51, wherein the crystalline form of ralinepag is characterized as having:
an XRPD pattern substantially the same as shown in FIG. 2 as measured using Cu Kα.radiation; and
a Thermogravimetric/Differential Thermal Analysis (TGA/DTA) thermogram substantially the same as shown in FIG. 8.

### Claim 56 (depends on 51)

The crystalline form of ralinepag of claim 51, wherein the crystalline form of ralinepag is characterized as having:
an XRPD pattern with peaks at 3.6±0.2°2-Theta, 18.7±0.2°2-Theta, and 22.2±0.2°2-Theta as measured using Cu Kα.radiation; and
a Thermogravimetric Analysis (TGA) trace showing mass loss of about 17.8% from the onset of heating up to approximately 238° C. and a Differential Thermal Analysis (DTA) thermogram showing a sharp endothermic event having an onset at about 74.6° C.

### Claim 57 (depends on 51)

The crystalline form of ralinepag of claim 51, wherein the crystalline form of ralinepag is characterized as having:
an XRPD pattern substantially the same as shown in FIG. 3 as measured using Cu Kα.radiation; and
a Thermogravimetric/Differential Thermal Analysis (TGA/DTA) thermogram substantially the same as shown in FIG. 9.

### Claim 58 (depends on 51)

The crystalline form of ralinepag of claim 51, wherein the crystalline form of ralinepag is characterized as having:
an XRPD pattern with peaks at 15.0 0.2°2-Theta, 16.7±0.2°2-Theta, and 18.0±0.2°2-Theta as measured using Cu Kα.radiation; and
a Differential Thermal Analysis (DTA) thermogram showing a broad endothermic event having an onset at about 29.0° C., a sharp endothermic event having an onset at about 127.8° C., or both.

### Claim 59 (depends on 51)

The crystalline form of ralinepag of claim 51, wherein the crystalline form of ralinepag is characterized as having:
an XRPD pattern substantially the same as shown in FIG. 4 as measured using Cu Kα.radiation; and
a Thermogravimetric/Differential Thermal Analysis (TGA/DTA) thermogram substantially the same as shown in FIG. 10.

### Claim 60 (depends on 51)

A solid form pharmaceutical composition comprising the crystalline ralinepag of claim 51 and at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition is suitable for administration by oral administration, intranasal administration, or inhalation; or the pharmaceutical composition is in the form of a tablet, a pill, or a capsule; or the pharmaceutical composition is suitable for administration with a dry powdered inhaler (DPI) or a metered dose inhaler (MDI).

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60, wherein the pharmaceutical composition is a tablet, a pill, or a capsule.

### Claim 62 (depends on 60)

The pharmaceutical composition of claim 60, wherein the pharmaceutical composition is suitable for administration with a dry powdered inhaler (DPI) or a metered dose inhaler (MDI).

### Claim 63 (depends on 51)

A method of treating pulmonary arterial hypertension (PAH) in a subject in need thereof, comprising administering the crystalline form of ralinepag of claim 51, wherein the subject has World Health Organization (WHO)/New York Heart Association (NYHA) functional class II to IV symptoms.
